Form 4: Lilly Endowment Inc. Sells Shares in Eli Lilly & Co.

Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a substantial number of shares on July 8, 2024, at various prices.

Summary

• Lilly Endowment Inc. sold a total of 92,413 shares of Eli Lilly & Co. common stock on July 8, 2024.
• The sales were executed in multiple transactions at prices ranging from $915.00 to $928.495 per share.
• The transactions resulted in a decrease in Lilly Endowment Inc.'s holdings of Eli Lilly & Co. stock to 97,153,810 shares.
• The sales were conducted at weighted average prices for each block of shares sold.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing detailing a stock sale, with no inherent positive or negative sentiment.

Industry Context

This Form 4 filing is a routine disclosure of stock transactions by a major shareholder, Lilly Endowment Inc., and is a normal part of regulatory compliance for publicly traded companies like Eli Lilly & Co.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting insider transactions in publicly traded companies, such as Eli Lilly & Co.
• The level of detail provided, including weighted average prices and price ranges, is consistent with SEC requirements for these filings.
• Similar filings are made by other major shareholders and company insiders across the pharmaceutical industry, such as those at Pfizer, Merck, and Johnson & Johnson.

Stakeholder Impact

• The sale of shares by a major shareholder like Lilly Endowment Inc. could potentially have a minor impact on the stock price of Eli Lilly & Co.

Key Dates

Keywords

Eli Lilly & Co, Lilly Endowment Inc, share sale, stock transaction, insider trading, Form 4